Changing the Disease Course in HCC

On 11 September, we heard from Professor Arndt Vogel, Professor Sandrine Faivre and Professor Josep Llovet, as part of the Ipsen-sponsored symposium ‘Changing the disease course in HCC: Current evidence and future insights’.
Professor Faivre summarised the current evidence from the most recent Phase III studies in advanced HCC. An area in which we have seen tremendous progress in recent years, following the approval of several new TKIs, alongside other VEGF targeted agents and most recently the positive data from the
combination of atezolizumab and bevacizumab. This combination is conditionally likely to become the new standard of care in 1st-line HCC treatment. READ MORE

ILCA Highlights